ealy stage clinical biotech with 15 Phase2 clinical trials of 3 diffrent drugs: PanzemNCD (2ME2 nanocrytaldispersion); MKC-1, ENMD=-1198. Drugs have multimechanisms of action and are being used for a multiplicity of cancers( glioblastoma multiforme, nslc-lung-, ovarian, kidney, multiple myeloma, prostate, advanced cancers, and Panzem is slated to be used also in inflammatory diseases, most notably rheumatoid arthritis. Celgene owns 27.22% ofd voting stock, large ownership by insiders and institutions; cash on hand to go well into second half of 2008 with no debt. An ambitoius program with an administration which in the past 2 yers has met its deadliners on time; multiple other drugs in pipeline; impending partnership for its aurura kinase inhibitor with Big Pharma company . Will be presenting 3 papers at ASCO June 1 through June 6, 2007 Currently unknown and underpriced

celgene- need I say more; a very early investor and have hung on since for the rewarding ride (up more than 5,300% in the past 10 yrs)

a sleeper biotech- will be running Phase 3 trials for bone cancer

a real winner in niche markets